Overview

Modeling the Psychopathological Dimensions of Schizophrenia: From Molecules to Behavior is the first book to offer a comprehensive review of the new theoretical, clinical, and basic research framework that considers psychotic illness as a group of dimensional representations of psychopathology rather than as traditional distinct categorical diagnoses. Psychotic illness, typified by schizophrenia, is a devastating condition increasingly recognized as a disorder of abnormal brain development and dysconnectivity. Its complex etiology involves both genetic and environmental factors, as well as the interplay among them. This book describes the current understanding of the clinical and pathological features of schizophrenia, with a particular focus on the evolving conceptualization of schizophrenia and related diagnostic categories of psychotic illness as combinations of dimensional abnormalities. It provides an overview of modern strategies for generating cellular and whole animal models of schizophrenia as well as detailed reviews of the specific experimental preparations and paradigms aimed at molecular, developmental, and brain-network mechanisms that are the underlying aspects of abnormal behavior and various aspects of schizophrenia. This groundbreaking book is an authoritative overview of the translational impact of emerging clinical insights on basic research approaches in schizophrenia that will advance the reader’s understanding of the five major dimensions of psychopathology in schizophrenia and related psychoses and resolve the genetic and neurobiological underpinnings of these dimensions.

Full Product Details

9780128009819

Table of Contents

Reviews

Author Information

Mikhail V. Pletnikov, M.D., Ph.D. is Professor in Department of Psychiatry at Johns Hopkins University School of Medicine. He received his M.D. in 1986 from I.M. Sechenov Moscow Medical Academy, Moscow, Russia and his Ph.D. in Normal Physiology in 1990 from P.K. Anokhin Institute of Normal Physiology, Moscow, Russia. He did his post-doctoral training under Dr Timothy H. Moran (1996-1999) at the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and under Dr Kathryn M. Carbone (1996-1999) at the laboratory of pediatric and respiratory viral infections, the Center for Biologics Evaluation and Research (CBER), the U.S. Food and Drug Administration. He joined faculty in Department of Psychiatry at Johns Hopkins University in 1999. His current research interests focus on understanding pathogenesis of human psychiatric disease with neurodevelopmental origin, e.g., schizophrenia and autism with particular emphasis on a role of gene-environment interactions and the neuro-immune interplay in the complex pathogenesis of psychiatric conditions. Dr Pletnikov is also Director of the Behavioral Core at the School of Medicine. John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder. John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available